Abpro bags $60M in near-term R&D cash in tie-up with Chi­na's NJCT­TQ, with eyes on bis­pe­cif­ic T cell en­gagers

As Abpro march­es to­ward hu­man test­ing for its first im­muno-on­col­o­gy drug, the Woburn, MA-based syn­thet­ic bi­ol­o­gy play­er has scored $60 mil­lion in a siz­able de­vel­op­ment deal with a Chi­nese part­ner.

The part­ner­ship with NJCT­TQ — a sto­ried phar­ma with a fleet of R&D and sales staffers in Chi­na — marks Abpro’s first high pro­file pact since ty­ing up with As­traZeneca’s Med­Im­mune three years ago. And the two deals share the same fo­cus: bis­pe­cif­ic an­ti­bod­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.